COMMUNIQUÉS West-GlobeNewswire

Legend Biotech to Showcase CARVYKTI® Leadership and Next-Generation Cell Therapy Innovation at ASH 2026
04/11/2026
New CARTITUDE-4 subgroup analyses provide further insights into durable clinical outcomes with CARVYKTI in earlier-line treatment Updated data to be presented from first-in-human trial of LB2501, an investigational, off [...]
Kamau Therapeutics Announces First Multi-Patient Clinical Data Showing Precise Correction of the Sickle Cell Mutation and Restoration of Adult Hemoglobin
04/11/2026
All three patients are transfusion-independent with no vaso-occlusive events; predominant adult hemoglobin profile restored, with sickle hemoglobin below 20% beyond six months Data to be featured in an oral presentation [...]
Climb Bio to Present New Data for Budoprutug in Immune Thrombocytopenia at the 68th American Society of Hematology Annual Meeting and Exposition
04/11/2026
WELLESLEY HILLS, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that [...]
Atavistik Bio to Highlight Momentum Across Hematology Pipeline with Harmony-HHT Clinical Trial Update and New Preclinical Data from HHT and JAK2 V617F Programs at ASH 2026
04/11/2026
Harmony-HHT trial-in-progress poster to showcase the ongoing Phase 1/2 clinical study of ATV-1601, an investigational oral, AKT1-selective allosteric inhibitor targeting the underlying disease biology of hereditary [...]
Umoja Biopharma Announces Oral Presentation of First UB-VV400 In Vivo CAR T Cell Therapy Clinical Data and Four Total Presentations at the 68th ASH Annual Meeting
04/11/2026
Presentations span UB-VV400 and UB-VV410 clinical data from investigator-initiated trials and trial-in-progress posters for UB-VV400 and UB-VV500 SEATTLE, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja [...]
Secura Bio Announces Two Duvelisib Presentations on Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma at the 2026 American Society of Hematology Annual Meeting
04/11/2026
Phase 2 PRIMO sub-analysis highlights outcomes with duvelisib in patients with peripheral T-cell lymphoma who proceeded to stem cell transplant Novel topical formulation of duvelisib in cutaneous T-cell lymphoma [...]
Corvus Pharmaceuticals Announces Initial Data from Soquelitinib Clinical Trial in Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) will be Presented at the 68ᵗʰ American Society for Hematology Annual Meeting & Exposition
04/11/2026
Data shows positive one-year safety and efficacy data from three patients enrolled in ongoing Phase 2 clinical trial being led by researchers at the National Institute of Allergy and Infectious Diseases (NIAID) Safety [...]
Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026
04/11/2026
NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the Company will host an in- [...]
Phase 1 Data for CITY-FXI, an RNAi Therapeutic Candidate for Thromboembolic Diseases, Selected for Oral Presentation at the 68th ASH Annual Meeting
04/11/2026
Preclinical data supporting CITY-TFR2 for anemia of chronic disease to be presented in a poster session CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- City Therapeutics, Inc. (Nasdaq: CTY), a clinical-stage [...]
Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory Large B-Cell Lymphoma
04/11/2026
Ronde-cel achieved a 91% overall response rate and 77% complete response rate; median progression-free survival not reached and estimated 6-month duration of complete response of 92% in 44 patients with 3L+ R/R LBCL in [...]
Agios to Highlight Strength and Differentiation of Rare Hematology Portfolio with New Clinical Data for Mitapivat in Sickle Cell Disease and AG-236 in Polycythemia Vera at ASH 2026
04/11/2026
14 abstracts accepted at ASH 2026, including three oral presentations featuring new data across mitapivat clinical programs New analyses from RISE UP Phase 3 trial of mitapivat in sickle cell disease show durable [...]
CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition
04/11/2026
ZUG, Switzerland and BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data in patients with relapsed or refractory large B-cell lymphoma from the ongoing Phase 1 [...]
Lakefront Biotherapeutics Announces Poster Presentation at the 2026 American Society of Hematology Meeting
04/11/2026
Gamgertamig data from ongoing Phase 1b studies suggest potential to retain remission after B cell reconstitution, maintained in the absence of background therapy for autoimmune cytopenias, consistent with an “immune [...]
Lyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA Submission
04/11/2026
Investors include ARCH Venture Partners, Adage Capital Management LP, Caligan Partners LP, RTW Investments, a leading mutual fund and other new and existing institutional investors. Ronde-cel, a next-generation CD19/ [...]
Solu Therapeutics to Present Initial Phase 1 Results of STX-0712 and New Preclinical Data on STX-0640 in Two Oral Presentations at the 2026 ASH Annual Meeting
04/11/2026
BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer and immunology, today announced that initial results from its [...]
Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026
04/11/2026
– Two oral presentations to feature first ziftomenib combination data with quizartinib in newly diagnosed and gilteritinib in relapsed/refractory NPM1/FLT3 co-mutated AML – – Longer-term Phase 1b data for ziftomenib [...]
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition
04/11/2026
First clinical data for sutacimig in Factor VII deficiency (FVIID) shows multi-fold accumulation of endogenous FVII(a) with shortening of prothrombin time after a single subcutaneous dose in initial participants of the [...]
Daré Bioscience to Present at Stifel’s 2026 Healthcare Conference
04/11/2026
SAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world [...]
Tangram Announces Oral Presentation of TGM-148 Preclinical Data Highlighting Context-Dependent Mechanism of Action at the American Society of Hematology (ASH) 2026 Annual Meeting
04/11/2026
TGM-148 enhances thrombin generation in impaired hemostasis No thrombotic safety signals at repeat toxicology doses in healthy non-human primates Phase 1 trial in healthy volunteers underway, with initial data [...]

Pages